首页> 美国卫生研究院文献>Current Therapeutic Research Clinical and Experimental >Effectiveness and tolerability of NSAIDs in the prophylaxis of pancreatitis after endoscopic retrograde cholangiopancreatography: A systematic review and meta-analysis
【2h】

Effectiveness and tolerability of NSAIDs in the prophylaxis of pancreatitis after endoscopic retrograde cholangiopancreatography: A systematic review and meta-analysis

机译:NSAIDs预防内镜逆行胰胆管造影术后胰腺炎的有效性和耐受性:系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP). The beneficial effects of pharmaco-logic treatment of acute pancreatitis are unclear. Although the prophylactic use of NSAIDs for the reduction of the risk for pancreatic injury after ERCP has been assessed, the beneficial effects of NSAIDs on pancreatic injury are still being debated.>Objective: The aim of this study was to determine the effectiveness and tolerability of NSAIDs in the prophylaxis of post-ERCP pancreatitis (PEP).>Methods: MEDLINE (January 1966–January 2009), EMBASE (January 1966–January 2009), and the Cochrane Central Register of Controlled Trials (Issue 1, 2009) were searched using the key terms: pancreatitis, post-ERCP pancreatitis, nonsteroidal anti-inflammatory drugs, indomethacin, and diclofenac. The methods recommended by the Cochrane Collaboration and the Quality of Reporting Meta-Analyses guideline were used to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) of NSAIDs in the prevention of PEP.>Results: Four multinational RCTs were included in the meta-analysis (969 patients). The pooled odds ratio for NSAIDs for mild PEP was 0.69 (95% CI, 0.40–1.17; P = NS); moderate to severe PEP, 0.22 (95% CI, 0.05–1.01; P = 0.05); PEP (pooled), 0.44 (95% CI, 0.21–0.93; P = 0.03); in high-risk patients, 0.49 (95% CI, 0.17–1.39; P = NS); and in low-risk patients, 0.29 (95% CI, 0.12–0.71; P = 0.006). No evidence of publication bias was found.>Conclusion: Based on the findings from the present systematic review of 4 RCTs, NSAIDs were effective and well tolerated in the prevention of PEP, especially in low-risk patients.
机译:>背景:急性胰腺炎是内镜逆行胰胆管造影术(ERCP)的常见并发症。药物治疗急性胰腺炎的益处尚不清楚。尽管已评估了NSAID预防性使用以降低ERCP后胰腺损伤的风险,但仍在争论NSAID对胰腺损伤的有益作用。>目的:本研究的目的是:确定NSAIDs在预防ERCP后胰腺炎(PEP)中的有效性和耐受性。>方法: MEDLINE(1966年1月至2009年1月),EMBASE(1966年1月至2009年1月)和Cochrane Central使用以下关键词搜索对照试验的登记册(2009年第1期):胰腺炎,ERCP后胰腺炎,非甾体抗炎药,消炎痛和双氯芬酸。通过Cochrane合作建议的方法和报告的荟萃分析质量指南,对NSAID的随机对照试验(RCT)进行PEP预防的系统评价和荟萃分析。>结果:荟萃分析包括四项跨国RCT(969例患者)。轻度PEP的NSAID合并比值比为0.69(95%CI,0.40-1.17; P = NS);中度至重度PEP,0.22(95%CI,0.05-1.01; P = 0.05); PEP(合并),0.44(95%CI,0.21-0.93; P = 0.03);高危患者为0.49(95%CI,0.17-1.39; P = NS);低危患者为0.29(95%CI,0.12-0.71; P = 0.006)。没有发现任何发表偏倚的证据。>结论:根据目前对4篇RCT的系统评价发现,NSAID在预防PEP(尤其是低危患者)方面是有效且耐受性良好的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号